💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Bayer shares jump on report of U.S. antitrust deal on Monsanto

Published 04/10/2018, 04:52 AM
© Reuters. FILE PHOTO: The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal
DJI
-
BASFN
-
BAYGN
-
DD
-
MON
-

FRANKFURT (Reuters) - Bayer (DE:BAYGn) shares jumped nearly 5 percent on Tuesday following a media report that the U.S. Justice Department will allow the German drugs and pesticides group to acquire Monsanto (N:MON) in a $62.5 billion deal.

The Justice Department reached an agreement in principle with Bayer and Monsanto in recent days after the companies agreed to sell more assets, the Wall Street Journal said late on Monday, citing people familiar with the matter.

Under the deal, Bayer agreed to sell additional seed and treatment assets to BASF (DE:BASFn) and agreed to make concessions related to digital agriculture, it said.

Bayer shares rose 4.7 percent by 0800 GMT to reach a one-month high.

Baader Helvea analyst Markus Mayer said he expects the concessions granted to the Justice Department probably did not go far beyond asset sales already agreed with the European Commission.

"The selling of these assets and the rights issue ... should start therefore soon and should be positive triggers for the stock," Mayer said, adding the rights issue should be smaller than initially expected.

Shares of Monsanto, the world's biggest seed company, approached a four-year high on the news in New York on Monday, before closing up 6.2 percent at $125.15.

The takeover, one of a trio of major deals in the agribusiness sector in recent years, would create a company with a share of more than a quarter of the world's seed and pesticides market. A souring global farm economy has spurred consolidation among the major players, triggering protests from environmental and farming groups worried about their market power.

The deal reduces competition for sales of seeds and chemicals to farmers struggling with low crop prices, raising the risk for price gouging, said Wenonah Hauter, executive director for Food & Water Watch, an advocacy group.

"The Justice Department's paltry divestment approach does little to address the extreme control the merged firm will have over farmers' data, genetics, biotechnology traits or the associated agrichemical industry," she said.

Bayer declined comment on the report, but said in a statement it still anticipated closing the Monsanto purchase in the second quarter.

BASF, Monsanto and the Justice Department declined to comment.

Last week, Monsanto said in a quarterly earnings report that it was confident the U.S. and other needed regulatory approvals would be secured within the second quarter. Monsanto did not host its usual conference call with analysts to discuss the earnings because of the pending merger.

The Justice Department said last month that it was still reviewing the deal and noted that genetically modified seeds are largely prohibited in Europe but widely used throughout the United States.

European Union antitrust regulators approved the deal in March after the companies agreed to sell a swathe of assets to BASF. China, Brazil and Australia have also approved the proposed merger.

© Reuters. FILE PHOTO: The logo of Bayer AG is pictured at the Bayer Healthcare subgroup production plant in Wuppertal

The deal was preceded by a merger of Dow (N:DWDP) and Dupont and a tie-up of ChemChina [CNNCC.UL] and Syngenta.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.